<\/p>\n
A Nasdaq-listed biotech company is betting big on crypto with a $50 million move into Hyperliquid\u2019s HYPE token.<\/p>\n
According to a June 17 press <\/a>release<\/a> from Eyenovia, Inc., a U.S.-based ophthalmic technology firm, the company has secured $50 million in private equity financing to accumulate over 1 million Hyperliquid (HYPE) tokens. With this move, Eyenovia becomes the first publicly traded U.S. company to hold HYPE in its treasury and operate as a Hyperliquid blockchain validator.<\/p>\n The funding deal includes convertible preferred shares and warrants, which could raise up to $150 million if fully exercised. Alongside the announcement, Eyenovia named Hyunsu Jung as chief investment officer and board member to oversee the new digital asset strategy.<\/p>\n \u201cWe\u2019re pleased to join the growing number of companies adopting cryptocurrency treasury strategies,\u201d said chief executive officer Michael Rowe. \u201cWe believe this move supports long-term capital appreciation and shareholder value.\u201d<\/p>\n <\/p>\n Jung called HYPE \u201cthe most robust digital asset,\u201d citing Hyperliquid\u2019s rapid growth and leading onchain revenue. HYPE ranks as the 12th-largest cryptocurrency by market cap, having surged 380% from its April low to an all-time high of $45.57 on June 16. At press time, HYPE is trading at $40.24, down 11% from its peak.<\/p>\n